Catalyst Pharmaceutical CPRX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $596.96M+11.7% | $588.99M+19.8% | $578.2M+25.6% | $558.5M+28.5% | $534.65M+30.0% | ||
| $83.82M+12.9% | $87.25M+26.7% | $82.82M+31.4% | $79.45M+37.2% | $74.24M+36.1% | ||
| $513.14M+11.5% | $501.74M+18.6% | $495.37M+24.6% | $479.05M+27.2% | $460.41M+29.0% | ||
| 86%-0.2pp | 85.2%-0.8pp | 85.7%-0.6pp | 85.8%-0.9pp | 86.1%-0.6pp | ||
| $11.48M-17.7% | $12.71M+0.5% | $14.7M+35.8% | $15.33M-83.2% | $13.95M-84.9% | ||
| $196.16M+10.4% | $193.75M+9.0% | $184.52M+5.1% | $182.93M+12.0% | $177.71M+17.7% | ||
| $267.64M+15.7% | $257.78M+32.1% | $258.78M+48.7% | $243.42M+183% | $231.37M+195% | ||
| 44.8%+1.6pp | 43.8%+4.1pp | 44.8%+7.0pp | 43.6%+23.8pp | 43.3%+24.2pp | ||
| $28.82M+6.3% | $25.74M+21.8% | $27.02M+82.4% | $28.55M+271% | $27.1M+240% | ||
| $296.46M+14.7% | $283.52M+31.1% | $285.8M+51.4% | $271.97M+191% | $258.46M+200% | ||
| $75.14M+23.0% | $69.19M+32.1% | $68.23M+48.4% | $63.3M+149% | $61.11M+189% | ||
| $221.32M+12.1% | $214.33M+30.8% | $217.56M+52.4% | $208.67M+206% | $197.35M+203% | ||
| 37.1%+0.2pp | 36.4%+3.1pp | 37.6%+6.6pp | 37.4%+21.7pp | 36.9%+21.1pp | ||
| $1.74+10.8% | $1.69+29.0% | $1.72+45.8% | $1.65+206% | $1.57+191% | ||
| $1.81+9.7% | $1.76+27.5% | $1.79+43.2% | $1.73+193% | $1.65+175% | ||
| 508.8M+1.4% | 508.8M+2.1% | 506.5M+4.0% | 504.9M+7.8% | 502M+9.7% | ||
| 489.3M+2.6% | 488.5M+3.4% | 484.7M+5.3% | 481M+7.4% | 477M+9.4% | ||
| $37.86M+1.3% | $37.5M+0.3% | $37.38M+0.8% | $37.38M+3.2% | $37.38M+5.7% | ||
| $221.35M+12.2% | $214.26M+30.7% | $217.56M+52.4% | $208.7M+206% | $197.33M+203% | ||
| $329.32M+8.6% | $331.21M+11.7% | $319.42M+11.5% | $315.08M-9.6% | $303.28M-8.9% | ||
| $25K+247% | -$64K-228% | $0+100% | $31K+263% | -$17K-54.5% | ||
| $28.82M+6.3% | $25.74M+21.8% | $27.02M+82.4% | $28.55M+271% | $27.1M+240% | ||
| $596.96M+11.7% | $588.99M+19.8% | $578.2M+25.6% | $558.5M+28.5% | $534.65M+30.0% | ||
| $267.64M+15.7% | $257.78M+32.1% | $258.78M+48.7% | $243.42M+183% | $231.37M+195% | ||
| $305.83M+13.6% | $295.65M+26.9% | $296.57M+40.3% | $281.25M+130% | $269.17M+136% | ||
| $305.83M+13.6% | $295.65M+26.9% | $296.57M+40.3% | $281.25M+130% | $269.17M+136% | ||
| 51.2%+0.9pp | 50.2%+2.8pp | 51.3%+5.4pp | 50.4%+22.2pp | 50.3%+22.6pp | ||
| $267.64M+15.7% | $257.78M+32.1% | $258.78M+48.7% | $243.42M+183% | $231.37M+195% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Catalyst Pharmaceutical's profit margins?
- Gross margin is 86.0% and operating margin is 44.8%, with a 37.1% net margin.
- Where does Catalyst Pharmaceutical's income statement data come from?
- Every line is extracted from Catalyst Pharmaceutical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.